Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 1621 AL 1635

Histone Deacetylases as Epigenetic Targets for Treating Parkinson's Disease

Li Y, Gu Z, Lin S, Chen L, Dzreyan V, Eid M, Demyanenko S, He B.

Brain Sci. 2022 May 21;12(5):672. doi: 10.3390/brainsci12050672.

Lyso-IP: Uncovering Pathogenic Mechanisms of Lysosomal Dysfunction

Chen C, Sidransky E, Chen Y.

Biomolecules. 2022 Apr 21;12(5):616. doi: 10.3390/biom12050616.

Comparative Analysis of the Relative Fragmentation Stabilities of Polymorphic Alpha-Synuclein Amyloid Fibrils

Sanami S, Purton TJ, Smith DP, Tuite MF, Xue WF.

Biomolecules. 2022 Apr 25;12(5):630. doi: 10.3390/biom12050630.

Cerebral Iron Deposition in Neurodegeneration

Dusek P, Hofer T, Alexander J, Roos PM, Aaseth JO.

Biomolecules. 2022 May 17;12(5):714. doi: 10.3390/biom12050714.

Parkinson's Disease and SARS-CoV-2 Infection: Particularities of Molecular and Cellular Mechanisms Regarding Pathogenesis and Treatment

Anghelescu A, Onose G, Popescu C, Băilă M, Stoica SI, Postoiu R, Brumă E, Petcu IR, Ciobanu V, Munteanu C.

Biomedicines. 2022 Apr 26;10(5):1000. doi: 10.3390/biomedicines10051000.

Adeno-Associated Viruses for Modeling Neurological Diseases in Animals: Achievements and Prospects

Lunev E, Karan A, Egorova T, Bardina M.

Biomedicines. 2022 May 15;10(5):1140. doi: 10.3390/biomedicines10051140.

Brain-Derived Neurotropic Factor in Neurodegenerative Disorders

Ibrahim AM, Chauhan L, Bhardwaj A, Sharma A, Fayaz F, Kumar B, Alhashmi M, AlHajri N, Alam MS, Pottoo FH.

Biomedicines. 2022 May 16;10(5):1143. doi: 10.3390/biomedicines10051143.

TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications

Luo J.

Biomedicines. 2022 May 23;10(5):1206. doi: 10.3390/biomedicines10051206.

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism

Furderer ML, Hertz E, Lopez GJ, Sidransky E.

Int J Mol Sci. 2022 May 23;23(10):5842. doi: 10.3390/ijms23105842.

Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases

Gentile G, Morello G, La Cognata V, Guarnaccia M, Conforti FL, Cavallaro S.

J Pers Med. 2022 May 10;12(5):770. doi: 10.3390/jpm12050770.

Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities

Fabbri M, Coelho M, Garon M, Biundo R, Mestre TA, Antonini A, On Behalf Of iCARE-Pd Consortium.

J Pers Med. 2022 May 18;12(5):813. doi: 10.3390/jpm12050813.

Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases

Rao IY, Hanson LR, Johnson JC, Rosenbloom MH, Frey WH 2nd.

Pharmaceuticals (Basel). 2022 Apr 29;15(5):551. doi: 10.3390/ph15050551.

Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier

Teleanu RI, Preda MD, Niculescu AG, Vladâcenco O, Radu CI, Grumezescu AM, Teleanu DM.

Pharmaceutics. 2022 May 4;14(5):987. doi: 10.3390/pharmaceutics14050987.

Consecutive Kummell's Disease Combined with Parkinson's Disease and Experienced Internal Fixation Failure: A Case Report and Literature Review

Zhan Y, He G, Yang H, Gao W, Yuan W, Sun H, Hao D, Wang B.

Orthop Surg. 2022 Jul;14(7):1533-1540. doi: 10.1111/os.13260. Epub 2022 May 27.

Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1

Manfready RA, Forsyth CB, Voigt RM, Hall DA, Goetz CG, Keshavarzian A.

Curr Neurol Neurosci Rep. 2022 Jul;22(7):335-342. doi: 10.1007/s11910-022-01196-5. Epub 2022 May 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias